Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
<div><p>Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies. Response rates are however suboptimal, and despite considerable efforts, predicting response to immune checkpoint inhibitors a...
محفوظ في:
| المؤلف الرئيسي: | Allan Relecom (14153295) (author) |
|---|---|
| مؤلفون آخرون: | Maysaloun Merhi (4246147) (author), Varghese Inchakalody (15263530) (author), Shahab Uddin (154400) (author), Darawan Rinchai (742366) (author), Davide Bedognetti (2632474) (author), Said Dermime (79420) (author) |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
حسب: Reem Saleh (3513056)
منشور في: (2019) -
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
حسب: Reem Saleh (3513056)
منشور في: (2019) -
Immune checkpoint inhibitors: recent progress and potential biomarkers
حسب: Pramod Darvin (153341)
منشور في: (2018) -
Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
حسب: Shayista Akbar (14442117)
منشور في: (2023) -
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
حسب: Reem Saleh (3513056)
منشور في: (2020)